We are the lung research center of the Leibniz Association. Our main focus: Common diseases such as asthma, allergies and chronic obstructive pulmonary disease (COPD), as well as infection-related inflammation of the lungs, in particular tuberculosis (TB).
The program area is dedicated to research into asthma, COPD and allergies, as these are among the most common chronic diseases and therefore cause an enormous burden for both patients and healthcare systems.
The Infections program area is dedicated to researching and combating bacterial infectious diseases of the lung with a focus on tuberculosis. The aim is to improve the control and treatment of this disease.
Tuberculosis: Scientists develop novel drug candidate for combating resistant pathogens
Researchers at Martin Luther University Halle-Wittenberg (MLU) and the Research Center Borstel, Leibniz Lung Center have developed a promising new substance for targeting bacteria that cause tuberculosis. The team have produced a compound that inhibits the pathogens’ ability to produce energy and causes them to die. Established drugs work in a similar fashion, but the pathogen is becoming increasingly resistant to these medications. The study was conducted joi
08.12.2025
Neues Weißbuch zeigt: Allergien stellen eine wachsende Herausforderung dar
Die fünfte, umfassend überarbeitete und erweiterte Auflage des „Weißbuch Allergie in Deutschland“ ist im Oktober dieses Jahres im Springer Medizin Verlag erschienen. Ein zentraler inhaltlicher Beitrag dieses Standardwerks stammt auch in dieser Auflage von Prof. Uta Jappe vom Forschungszentrum Borstel, Leibniz Lungenzentrum (FZB). Gemeinsam mit den Kollegen Jörg Kleine-Tebbe✝, Berlin, und Richard Brans, Osnabrück, beleuchtet sie darin aktuelle wissenschaftliche Er
08.12.2025
Antibiotic resistance can also make bacteria more vulnerable
Antibiotic resistance is one of the greatest challenges in modern medicine. A new study now shows that the pathogen Haemophilus influenzae can develop a previously unknown and genetically highly unstable resistance mechanism. This so-called unstable heteroresistance is often not detected by standard resistance tests, which can in the worst case lead to treatment failures. The underlying cause is genomic alterations in the ompP2 gene, which can revert back to their origin
Dr. Niklas Köhler
FG Gruppe_en: Center for Clinical Studies
Contact
Position:
Leiter Studienzentrum
Email:
This email address is being protected from spambots. You need JavaScript enabled to view it.